
    
      This is a multicenter, open-label, long-term, extension, phase 3 study to evaluate the safety
      and efficacy of long-term administration of TVP-1012 at 1 mg for another 26 weeks in
      participants with early Parkinson's disease who have completed the preceding TVP-1012/CCT-001
      (NCT02337725) study.

      Among participants of the TVP-1012/CCT-001 study, those consenting to participate in this
      study prior to complete the preceding study and fulfilling the eligibility criteria will be
      enrolled in this study. From the day after the Visit 8 of the preceding study, participants
      will receive 1 mg of TVP-1012 once daily for 26 weeks in an unblinded manner.
    
  